Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
HoyaHOCPF +3.50%97 Debt-to-EBITDA is 0.11 as of Jun. 2026, which is 10% above its 10-year median of 0.10. GuruFocus rates HOCPF with a GF Score™ of 97/100 and a GF Value™ of $164.15 (Fairly Valued). The stock has 1 warning sign investors should review. Among 469 Medical Devices & Instruments companies, Hoya ranks better than 89.77% on this metric.
Debt-to-EBITDA measures a company's ability to pay off its debt.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
The historical rank and industry rank for Hoya's Debt-to-EBITDA or its related term are showing as below:
HOCPF'
s Debt-to-EBITDA Range Over the Past 10 Years
Min: 0.02 Med: 0.1 Max: 0.26
Current: 0.11
During the past 13 years, the highest Debt-to-EBITDA Ratio of Hoya was 0.26. The lowest was 0.02. And the median was 0.10.
HOCPF's Debt-to-EBITDA is ranked better than 89.77% of 469
companies
in the Medical Devices & Instruments industry
Industry Median: 1.62
vs HOCPF: 0.11
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
Hoya Debt-to-EBITDA Related Terms
Hoya Debt-to-EBITDA Historical Data
* Premium members only.
The historical data trend for Hoya's Debt-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
HOCPF vs ISRG, BDX, MDLN: Debt-to-EBITDA Comparison
For the Medical Instruments & Supplies subindustry, Hoya's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Hoya Debt-to-EBITDA vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Hoya's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Hoya's Debt-to-EBITDA falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is four times the quarterly (Jun. 2026) EBITDA data.
Hoya (HOCPF) has a Debt-to-EBITDA of 0.11 as of Jun. 2026. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Hoya. This is 10% above median its historical median of 0.10. Over the past decade, Hoya's Debt-to-EBITDA has ranged from 0.02 to 0.26. According to the industry distribution chart, Hoya ranks #48 out of 469 companies in the Medical Devices & Instruments industry, placing it in the top 10.2%.
Is Hoya's Debt-to-EBITDA too high?
Hoya's current Debt-to-EBITDA of 0.11 is 10% above median its 10-year median of 0.10. Over the past 10 years, this metric has ranged from a low of 0.02 to a high of 0.26. The Medical Devices & Instruments industry median Debt-to-EBITDA is 1.62. Hoya's value of 0.11 is 93.2% below this industry median. Based on the distribution chart, Hoya ranks #48 out of 469 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Hoya has a GF Score™ of 97/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Hoya's Debt-to-EBITDA compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, Hoya ranks #48 out of 469 companies for Debt-to-EBITDA. This places Hoya in the top 10% of its industry — outperforming the majority of peers. The industry median Debt-to-EBITDA is 1.62. Hoya's value of 0.11 is 93.2% below this benchmark. Historically, Hoya's own Debt-to-EBITDA has ranged from 0.02 to 0.26 over the past decade. While the company's 10-year median is 0.10 vs. the industry median of 1.62, Hoya has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Medical Devices & Instruments company?
The median Debt-to-EBITDA among Medical Devices & Instruments companies is 1.62, based on 469 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Hoya's current Debt-to-EBITDA of 0.11 is 93.2% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Hoya. For the Medical Devices & Instruments industry, the median Debt-to-EBITDA is 1.62 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Hoya's current Debt-to-EBITDA is 0.11, which is 10% above median its own 10-year median of 0.10. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Hoya stock overvalued right now?
Based on GuruFocus' analysis, Hoya (HOCPF) is currently considered Fairly Valued. The stock's GF Value™ is $164.15, compared to a current price of $159.57 — trading 2.8% below its estimated fair value. The current Debt-to-EBITDA is 0.11, which is 10% above median its 10-year median of 0.10 and 93.2% below the Medical Devices & Instruments industry median of 1.62. Hoya's overall GF Score™ is 97/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For Hoya (HOCPF), the current Debt-to-EBITDA is 0.11 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Hoya (HOCPF) Overvalued in 2026?
Based on GuruFocus' analysis, Hoya stock appears to be undervalued.
The current stock price of $159.57 is trading 2.8% below its estimated GF Value™ of $164.15.
GuruFocus considers Hoya to be Fairly Valued.
Key valuation signals for HOCPF:
Debt-to-EBITDA: 0.11 (10% above median its 10-year median of 0.10)
GF Value™: $164.15 vs. price of $159.57 (2.8% below fair value)
Industry Position: 93.2% below the Medical Devices & Instruments median (#48 of 469)
No single metric tells the full story. See the HOCPF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Founded in 1941 in Tokyo as an optical glass production plant, Hoya is one of the largest eyeglass lens manufacturers in the world. Leveraging its technology know-how in glass manufacturing, Hoya entered the mask blanks business in 1974. Now although its life care business accounts for more than 60% of its total revenue, majority of its profit before tax comes from its higher-margin IT business.
97GF Score
Get the complete analysis for HOCPF
Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HOCPF has been successfully added to your 
